Rath A, Mishra A, Ferreira V, Hu C, Omerza G, Kelly K, et al. Functional Interrogation of Lynch Syndrome Associated MSH2 Missense Variants via CRISPR-Cas9 Gene Editing in Human Embryonic Stem Cells. Hum Mutat. 2019;: pubmed publisher

Bouvet D, Bodo S, Munier A, Guillerm E, Bertrand R, Colas C, et al. Methylation Tolerance-based Functional Assay to Assess Variants of Unknown Significance in the MLH1 and MSH2 Genes and Identify Patients With Lynch Syndrome. Gastroenterology. 2019;: pubmed publisher

He Y, Kaina B. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?. Int J Mol Sci. 2019;20: pubmed publisher

Makita K, Hara H, Sano E, Okamoto Y, Ochiai Y, Harada T, et al. Interferon-β sensitizes human malignant melanoma cells to temozolomide-induced apoptosis and autophagy. Int J Oncol. 2019;54:1864-1874 pubmed publisher

Navarro G, Varani K, Reyes Resina I, Sánchez de Medina V, Rivas Santisteban R, Sánchez Carnerero Callado C, et al. Cannabigerol Action at Cannabinoid CB1 and CB2 Receptors and at CB1-CB2 Heteroreceptor Complexes. Front Pharmacol. 2018;9:632 pubmed publisher

Dörsam B, Seiwert N, Foersch S, Stroh S, Nagel G, Begaliew D, et al. PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression. Proc Natl Acad Sci U S A. 2018;115:E4061-E4070 pubmed publisher

Martínez Pinilla E, Varani K, Reyes Resina I, Angelats E, Vincenzi F, Ferreiro Vera C, et al. Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors. Front Pharmacol. 2017;8:744 pubmed publisher

Tomaszowski K, Hellmann N, Ponath V, Takatsu H, Shin H, Kaina B. Uptake of glucose-conjugated MGMT inhibitors in cancer cells: role of flippases and type IV P-type ATPases. Sci Rep. 2017;7:13925 pubmed publisher

Khusnutdinov R, Boichuk S. Mechanisms of Sensitivity of Soft Tissue Sarcoma Cells to Temozolomide. Bull Exp Biol Med. 2017;163:260-262 pubmed publisher

Martínez Pinilla E, Rabal O, Reyes Resina I, Zamarbide M, Navarro G, Sánchez Arias J, et al. Two Affinity Sites of the Cannabinoid Subtype 2 Receptor Identified by a Novel Homogeneous Binding Assay. J Pharmacol Exp Ther. 2016;358:580-7 pubmed publisher

Olszko M, Adair J, Linde I, Rae D, Trobridge P, Hocum J, et al. Foamy viral vector integration sites in SCID-repopulating cells after MGMTP140K-mediated in vivo selection. Gene Ther. 2015;22:591-5 pubmed publisher

Ramirez Y, Mladek A, Phillips R, Gynther M, Rautio J, Ross A, et al. Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. Mol Cancer Ther. 2015;14:111-9 pubmed publisher

Kim J, Kim J, Kim J, Kim S, Chung H, Park C. HOXA10 is associated with temozolomide resistance through regulation of the homologous recombinant DNA repair pathway in glioblastoma cell lines. Genes Cancer. 2014;5:165-174 pubmed

Berthois Y, Delfino C, Metellus P, Fina F, Nanni Metellus I, Al Aswy H, et al. Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O?-methylguanine methyltransferase and promotes temozolomide responsiveness. Cancer Biol Ther. 2014;15:938-50 pubmed publisher

Zhu R, Baumann R, Penketh P, Shyam K, Sartorelli A. Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanine. J Med Chem. 2013;56:1355-9 pubmed publisher

Urban A, Upadhyaya P, Cao Q, Peterson L. Formation and repair of pyridyloxobutyl DNA adducts and their relationship to tumor yield in A/J mice. Chem Res Toxicol. 2012;25:2167-78 pubmed publisher

Penketh P, Shyam K, Baumann R, Ishiguro K, Patridge E, Zhu R, et al. A strategy for selective O(6)-alkylguanine-DNA alkyltransferase depletion under hypoxic conditions. Chem Biol Drug Des. 2012;80:279-90 pubmed publisher

Bobustuc G, Smith J, Maddipatla S, Jeudy S, Limaye A, Isley B, et al. MGMT inhibition restores ER? functional sensitivity to antiestrogen therapy. Mol Med. 2012;18:913-29 pubmed publisher

Shi G, Azoulay M, Dingli F, Lamaze C, Loew D, Florent J, et al. SNAP-tag based proteomics approach for the study of the retrograde route. Traffic. 2012;13:914-25 pubmed publisher

Apisarnthanarax N, Wood G, Stevens S, Carlson S, Chan D, Liu L, et al. Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type. Arch Dermatol. 2012;148:613-20 pubmed publisher

Cole N, Donaldson J. Releasable SNAP-tag probes for studying endocytosis and recycling. ACS Chem Biol. 2012;7:464-9 pubmed publisher

Hussain A, Kampmeier F, von Felbert V, Merk H, Tur M, Barth S. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Bioconjug Chem. 2011;22:2487-95 pubmed publisher

Warren K, Gururangan S, Geyer J, McLendon R, Poussaint T, Wallace D, et al. A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J Neurooncol. 2012;106:643-9 pubmed publisher

Zhu R, Liu M, Luo M, Penketh P, Baumann R, Shyam K, et al. 4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine. J Med Chem. 2011;54:7720-8 pubmed publisher

Cai S, Wang H, Bailey B, Ernstberger A, Juliar B, Sinn A, et al. Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. Clin Cancer Res. 2011;17:2195-206 pubmed publisher

Vaidyanathan G, White B, Affleck D, McDougald D, Zalutsky M. Radioiodinated O(6)-Benzylguanine derivatives containing an azido function. Nucl Med Biol. 2011;38:77-92 pubmed publisher

Gupta S, Sathishkumar S, Ahmed M. Influence of cell cycle checkpoints and p53 function on the toxicity of temozolomide in human pancreatic cancer cells. Pancreatology. 2010;10:565-79 pubmed publisher

Zhang W, Wang Z, Shu F, Jin Y, Liu H, Wang Q, et al. Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J Biol Chem. 2010;285:40461-71 pubmed publisher

Stöhr K, Siegberg D, Ehrhard T, Lymperopoulos K, Oz S, Schulmeister S, et al. Quenched substrates for live-cell labeling of SNAP-tagged fusion proteins with improved fluorescent background. Anal Chem. 2010;82:8186-93 pubmed publisher

Kamiya M, Johnsson K. Localizable and highly sensitive calcium indicator based on a BODIPY fluorophore. Anal Chem. 2010;82:6472-9 pubmed publisher

Robinson C, Palomo J, Vogelbaum M. Thin layer chromatography-based assay of O6-methylguanine-DNA methyltransferase activity in tissue. Anal Biochem. 2010;405:263-5 pubmed publisher

Beard B, Trobridge G, Ironside C, McCune J, Adair J, Kiem H. Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. J Clin Invest. 2010;120:2345-54 pubmed publisher

Morales Ramirez P, Vallarino Kelly T, Cruz Vallejo V. Effect of O6-chloroethylguanine DNA lesions on the kinetics and mechanism of micronucleus induction in vivo. Environ Mol Mutagen. 2010;51:236-42 pubmed publisher

Konduri S, Ticku J, Bobustuc G, Sutphin R, Colon J, Isley B, et al. Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. Clin Cancer Res. 2009;15:6087-95 pubmed publisher

Martin L, Marples B, Coffey M, Lawler M, Hollywood D, Marignol L. Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity. Radiat Res. 2009;172:405-13 pubmed publisher

Tiwari R, Parang K. Protein conjugates of SH3-domain ligands and ATP-competitive inhibitors as bivalent inhibitors of protein kinases. Chembiochem. 2009;10:2445-8 pubmed publisher

Larochelle A, Choi U, Shou Y, Naumann N, Loktionova N, Clevenger J, et al. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. J Clin Invest. 2009;119:1952-63 pubmed publisher

Meany H, Warren K, Fox E, Cole D, Aikin A, Balis F. Pharmacokinetics of temozolomide administered in combination with O6-benzylguanine in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol. 2009;65:137-42 pubmed publisher

Lee A, Kahatapitiya P, Kramer B, Joya J, Hook J, Liu R, et al. Methylguanine DNA methyltransferase-mediated drug resistance-based selective enrichment and engraftment of transplanted stem cells in skeletal muscle. Stem Cells. 2009;27:1098-108 pubmed publisher

Davis B, Koc O, Reese J, Gerson S. O6-benzylguanine-resistant mutant MGMT genes improve hematopoietic cell tolerance to alkylating agents. Prog Exp Tumor Res. 1999;36:65-81 pubmed

Dolan M, Pegg A. O6-benzylguanine and its role in chemotherapy. Clin Cancer Res. 1997;3:837-47 pubmed